dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Shitara, Kohei |
dc.contributor.author | Doi, Toshihiko |
dc.contributor.author | Hosaka, Hisashi |
dc.contributor.author | Santoro, Armando |
dc.contributor.author | Longo-Muñoz, Federico |
dc.contributor.author | Alsina Maqueda, Maria |
dc.contributor.author | Thuss-Patience, Peter |
dc.date.accessioned | 2022-09-09T07:12:40Z |
dc.date.available | 2022-09-09T07:12:40Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Shitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, et al. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer. 2022 May;25:586–97. |
dc.identifier.issn | 1436-3305 |
dc.identifier.uri | https://hdl.handle.net/11351/8082 |
dc.description | Grups d'edat; Neoplàsies gastrointestinals; Trifluridina |
dc.description.sponsorship | This study was sponsored by Taiho Oncology, Inc., and Taiho Pharmaceuticals Co., Ltd. Professional medical writing and editorial assistance were provided by Vasupradha Vethantham, PhD, and Jennifer L. Robertson, PhD, at Ashfield MedComms, an Ashfield Health company, funded by Taiho Oncology, Inc. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Gastric Cancer;25 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esòfag - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Esophageal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10120-021-01271-9 |
dc.subject.decs | neoplasias del esófago |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1007/s10120-021-01271-9 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Shitara K, Doi T] Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa-shi, Japan. [Hosaka H] Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Gunma, Japan. [Thuss-Patience P] Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany. [Santoro A] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy. [Longo F] Medical Oncology, Hospital Universitario Ramon y Cajal, IRYCIS, CIBERONC, Madrid, Spain. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34997449 |
dc.identifier.wos | 000740186000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |